Comparative Pharmacology
Head-to-head clinical analysis: IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE versus ONMEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE versus ONMEL.
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE vs ONMEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Diphenhydramine is an antihistamine that antagonizes histamine H1 receptors.
ONMEL (omacetaxine mepesuccinate) inhibits protein synthesis by binding to the 80S ribosome and interfering with chain elongation, leading to apoptosis in leukemic cells.
1-2 tablets (200 mg ibuprofen/25 mg diphenhydramine HCl each) orally every 4-6 hours as needed; maximum 6 tablets in 24 hours.
50 mg orally twice daily for 14 days
None Documented
None Documented
Ibuprofen: 2-4 hours (immediate-release). Diphenhydramine: 8-12 hours (prolonged in hepatic impairment).
Terminal half-life 40–60 hours (mean 50 hours); allows once-daily dosing for systemic antifungal therapy.
Ibuprofen: Renal (90% as glucuronide conjugates, <10% unchanged). Diphenhydramine: Renal (primarily as metabolites, <10% unchanged). Both undergo hepatic metabolism with renal excretion of metabolites.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; >90% eliminated as metabolites in bile and feces.
Category D/X
Category C
NSAID
NSAID